Form 8-K Biomea Fusion, Inc. For: Oct 13

Wed, 14 Oct 2026 06:00:00 -0400

si-local-file:///var/storage/secattach/20261014/27183031.html

Biomea Fusion (BMEA) Reiterated at Market Outperform by Citizens on BMF-650 Ph1 Data

Wed, 14 Oct 2026 04:10:04 -0400

Citizens analyst Jonathan Wolleben reiterated a Market Outperform rating and $7.00 price target on Biomea Fusion Inc. (NASDAQ: BMEA).

The analyst commented, " Phase 1 data validate BMF-650 as an active and well-tolerated oral GLP candidate, with a profile that could support a strategic partnership; we reiterate our Market Outperform rating and $7 risk-adjusted, DCF-derived price target on Biomea Fusion."

For an analyst ratings summary and ratings history on Biomea Fusion Inc. click here. For more ratings news on Biomea Fusion Inc. click here.

Shares of Biomea Fusion Inc. closed at $1.26 yesterday.

Biomea Fusion reports Phase 1 weight loss data for oral GLP-1 drug

Tue, 13 Oct 2026 16:08:15 -0400

Biomea Fusion, Inc. (Nasdaq: BMEA) released Phase 1 clinical trial results for BMF-650, an investigational oral small-molecule GLP-1 receptor agonist, showing weight reductions across multiple dose cohorts over four weeks with mild tolerability outcomes.

In the randomized, double-blind, placebo-controlled GLP-131 study, mean weight reduction ranged from 1.5% to 3.2% at Day 29 across Cohorts 1 through 4, compared with 0.1% for pooled placebo. At doses of 200 mg or higher once daily, the mean weekly weight reduction was approximately 0.97 kg across those cohorts.

A fifth cohort, conducted under confinement, tested a rapid one-step titration in which participants received 200 mg once

Biomea Fusion Announces Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist

Tue, 13 Oct 2026 16:08:01 -0400

Mean weight reduction ranged from 1.5% to 3.2% at Day 29 across Cohorts 1-4, compared with 0.1% for pooled placebo.
No severe or serious TEAEs, no TEAE-related dose modifications, and no TEAE-related discontinuations among all BMF-650-treated MAD participants.
A rapid one-step titration to the target dose of 400 mg QD in Cohort 5 was equally well tolerated with all TEAEs being mild, with nausea and vomiting each reported in only 12.5% of participants, supporting further evaluation of “no titration” dosing for patients.
Company to host conference call on October 13 at 4:30 p.m. ET (1:30 p.m. PT).
Biomea Fusion Announces Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist

Tue, 13 Oct 2026 16:08:01 -0400
- Mean weight reduction ranged from 1.5% to 3.2% at Day 29 across Cohorts 1-4, compared with 0.1% for pooled placebo.
- No severe or serious TEAEs, no TEAE-related dose modifications, and no TEAE-related discontinuations among all BMF-650-treated MAD participants.
- A rapid one-step titration to the target dose of 400 mg QD in Cohort 5 was equally well tolerated with all TEAEs being mild, with nausea and vomiting each reported in only 12.5% of participants, supporting further evaluation of “no titration” dosing for patients.
- Company to host conference call on October 13 at 4:30 p.m. ET (1:30 p.m. PT).
  
  Biomea Fusion to release Phase I data for oral GLP-1 drug BMF-650
  
  Mon, 12 Oct 2026 16:31:01 -0400
  
  Biomea Fusion, Inc. (Nasdaq: BMEA) said it will release results from its Phase I GLP-131 clinical study evaluating BMF-650, an investigational oral small-molecule GLP-1 receptor agonist, on October 13, 2026.
  The San Carlos, California-based clinical-stage biopharmaceutical company said its management will host a conference call and webcast at 4:30 p.m. ET to discuss the findings.
  BMF-650 is one of two oral small-molecule therapies Biomea Fusion is developing, alongside icovamenib, targeting diabetes and obesity.
  
  Biomea Fusion to Announce Phase I Results for BMF-650, Its Next-Generation Oral Small-Molecule GLP-1 Receptor Agonist
  
  Mon, 12 Oct 2026 16:30:00 -0400
  
  SAN CARLOS, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company, today announced that it will report results from its Phase I GLP-131 clinical study evaluating BMF-650, an investigational next-generation oral small-molecule GLP-1 receptor agonist, on Tuesday, October 13, 2026. The Company will host a conference call and webcast at 4:30 p.m. ET (1:30 p.m. PT) to discuss the results.
  
  Conference Call and Webcast Details
  
  Biomea’s management will host a conference call and webcast on Tuesday, October 13, 2026, at 4:30 p.m. ET (1:30
  
  Biomea Fusion to Announce Phase I Results for BMF-650, Its Next-Generation Oral Small-Molecule GLP-1 Receptor Agonist
  
  Mon, 12 Oct 2026 16:30:00 -0400
  
  SAN CARLOS, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company, today announced that it will report results from its Phase I GLP-131 clinical study evaluating BMF-650, an investigational next-generation oral small-molecule GLP-1 receptor agonist, on Tuesday, October 13, 2026. The Company will host a conference call and webcast at 4:30 p.m. ET (1:30 p.m. PT) to discuss the results.
  
  Conference Call and Webcast Details
  
  Biomea’s management will host a conference call and webcast on Tuesday, October 13, 2026, at 4:30 p.m. ET (1:30
  
  Brookline Capital Markets Starts Biomea Fusion Inc. (BMEA) at Buy
  
  Wed, 07 Oct 2026 07:22:47 -0400
  
  Brookline Capital Markets analyst Kumaraguru Raja initiates coverage on Biomea Fusion Inc. (NASDAQ: BMEA) with a Buy rating and a price target of $10.00.
  The analyst comments "We are initiating coverage of Biomea Fusion with a Buy rating, and $10 TP. Biomea Fusion is developing icovamenib, an oral, covalent inhibitor of menin as a potentially disease-modifying therapy that can slow down or halt the progression of diabetes. Two, randomized, double-blind, placebo controlled Phase 2 clinical trials are ongoing for icovamenib in type 2 diabetes. Two Phase 2 clinical trials are being planned for icovamenib in type 1 diabetes. BMF-650 is a
  
  Brookline Capital Markets Starts Biomea Fusion Inc. (BMEA) at Buy
  
  Wed, 07 Oct 2026 07:22:47 -0400
  
  Brookline Capital Markets analyst Kumaraguru Raja initiates coverage on Biomea Fusion Inc. (NASDAQ: BMEA) with a Buy rating and a price target of $10.00.
  The analyst comments "We are initiating coverage of Biomea Fusion with a Buy rating, and $10 TP. Biomea Fusion is developing icovamenib, an oral, covalent inhibitor of menin as a potentially disease-modifying therapy that can slow down or halt the progression of diabetes. Two, randomized, double-blind, placebo controlled Phase 2 clinical trials are ongoing for icovamenib in type 2 diabetes. Two Phase 2 clinical trials are being planned for icovamenib in type 1 diabetes. BMF-650 is a
  
  Brookline Capital Markets Starts Biomea Fusion Inc. (BMEA) at Buy
  
  Wed, 07 Oct 2026 07:22:47 -0400
  
  Brookline Capital Markets analyst Kumaraguru Raja initiates coverage on Biomea Fusion Inc. (NASDAQ: BMEA) with a Buy rating and a price target of $10.00.
  The analyst comments "We are initiating coverage of Biomea Fusion with a Buy rating, and $10 TP. Biomea Fusion is developing icovamenib, an oral, covalent inhibitor of menin as a potentially disease-modifying therapy that can slow down or halt the progression of diabetes. Two, randomized, double-blind, placebo controlled Phase 2 clinical trials are ongoing for icovamenib in type 2 diabetes. Two Phase 2 clinical trials are being planned for icovamenib in type 1 diabetes. BMF-650 is a
  
  Biomea Fusion (BMEA) Reiterated at Market Outperform by Citizens - Time to 'Revisit This Story'
  
  Wed, 30 Sep 2026 04:13:46 -0400
  
  Citizens analyst Jonathan Wolleben reiterated a Market Outperform rating and $7.00 price target on Biomea Fusion Inc. (NASDAQ: BMEA).
  The analyst commented, " Last week, Clywedog Therapeutics (private) had Phase 1b data showing balomenib’s A1c control in T2D, while Caspian Therapeutics (private) unveiled a broad preclinical package at EASD for KO-7246. Both updates help validate menin inhibition’s ability to restore beta cell function and endogenous insulin production, which could mean transformative benefits for diabetics. ○ BMEA’s icovamenib is leading the way in the class, with clinical data in both T1D and T2D, with two Phase 2 readouts in 1Q27 and 2Q27,
  
  Biomea Fusion cancels planned public offering citing market conditions
  
  Wed, 23 Sep 2026 07:04:07 -0400
  
  Biomea Fusion, Inc. (Nasdaq: BMEA) announced it has terminated a proposed public offering of securities that was previously announced on Sept. 22, 2026.
  
  The clinical-stage diabetes and obesity company said its management determined that current market conditions were not conducive to an offering on terms favorable to stockholders. No securities were sold in connection with the proposed offering.
  
  The offering had been made pursuant to a shelf registration statement on Form S-3 filed with the U.S. Securities and Exchange Commission on Aug. 5, 2025, and declared effective by the SEC on Aug. 15, 2025. A preliminary prospectus supplement had been filed with
  
  Biomea Fusion Announces Termination of Proposed Public Offering of Securities
  
  Wed, 23 Sep 2026 07:03:00 -0400
  
  SAN CARLOS, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that it has terminated its proposed public offering of securities, previously announced on September 22, 2026. The termination results from an assessment by the Company's management that current market conditions are not conducive for an offering on terms that would be in the best interests of the Company's stockholders. No securities were sold in connection with the proposed offering.
  
  The offering was made by Biomea pursuant to a shelf registration statement
  
  Biomea Fusion Announces Termination of Proposed Public Offering of Securities
  
  Wed, 23 Sep 2026 07:03:00 -0400
  
  SAN CARLOS, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that it has terminated its proposed public offering of securities, previously announced on September 22, 2026. The termination results from an assessment by the Company's management that current market conditions are not conducive for an offering on terms that would be in the best interests of the Company's stockholders. No securities were sold in connection with the proposed offering.
  
  The offering was made by Biomea pursuant to a shelf registration statement
  
  Form 424B5 Biomea Fusion, Inc.
  
  Tue, 22 Sep 2026 16:08:00 -0400
  si-local-file:///var/storage/secattach/20260922/27091109.html
  
  Biomea Fusion launches public offering of common stock and warrants
  
  Tue, 22 Sep 2026 16:05:24 -0400
  
  Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage diabetes and obesity company based in San Carlos, Calif., announced the commencement of an underwritten public offering of shares of its common stock and pre-funded warrants to purchase shares of its common stock.
  
  The company stated that certain investors may receive pre-funded warrants in lieu of common stock. Biomea also intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the total shares of common stock and pre-funded warrants offered. All securities in the offering will be sold by Biomea.
  
  Konik Capital Partners, LLC, a division of T.R. Winston
  
  Biomea Fusion Announces Proposed Public Offering of Securities
  
  Tue, 22 Sep 2026 16:05:00 -0400
  
  SAN CARLOS, Calif., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, announced today that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. In addition, Biomea intends to grant the underwriter a 30-day option to purchase up to an additional fifteen percent (15%) of the total number of shares of common stock and pre-funded warrants in the proposed offering. All of the shares of common stock
  
  Biomea Fusion Announces Proposed Public Offering of Securities
  
  Tue, 22 Sep 2026 16:05:00 -0400
  
  SAN CARLOS, Calif., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, announced today that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. In addition, Biomea intends to grant the underwriter a 30-day option to purchase up to an additional fifteen percent (15%) of the total number of shares of common stock and pre-funded warrants in the proposed offering. All of the shares of common stock
  
  Form 8-K Biomea Fusion, Inc. For: Sep 22
  
  Tue, 22 Sep 2026 16:01:00 -0400
  si-local-file:///var/storage/secattach/20260922/27090988.html
  
  Increasing unusual call volume: CYPH BMEA KHC DPRO CBRG NAVN TTAN RARE SOLZ TSSI AADX BEAM AVAV
  
  Thu, 10 Sep 2026 09:58:19 -0400
  
  Increasing unusual call volume: CYPH BMEA KHC DPRO CBRG NAVN TTAN RARE SOLZ TSSI AADX BEAM AVAV
  
  Biomea Fusion, Inc. (BMEA) January 2.5 calls active
  
  Tue, 08 Sep 2026 05:30:01 -0400
  
  Biomea Fusion, Inc. (NASDAQ: BMEA) 30-day option implied volatility is at 108; compared to its 52-week range of 55 to 189 with a focus on January 2.5 calls.
  
  Increasing unusual call option volume: GPRO BMEA DPRO RARE INSW VSXY CHPT VRNS SYF EPYT
  
  Tue, 08 Sep 2026 04:44:53 -0400
  
  Increasing unusual call option volume: GPRO BMEA DPRO RARE INSW VSXY CHPT VRNS SYF EPYT
  Biomea Fusion to Participate in Upcoming Investor Conferences
  
  Thu, 03 Sep 2026 08:00:00 -0400
  
  SAN CARLOS, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Company” or “Company management”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that members of its management team will participate in the following upcoming investor conferences:
  - Citi's 2026 Biopharma Back to School Conference: Biomea will participate in one-on-one investor meetings on September 10, 2026, in New York, NY.
  - H.C. Wainwright 28^th Annual Global Investment Conference: Biomea will present at 11:00 a.m. ET on September 15, 2026, in New York, NY. Management will also participate in one-on-one investor meetings
  Biomea Fusion to Participate in Upcoming Investor Conferences
  
  Thu, 03 Sep 2026 08:00:00 -0400
  
  SAN CARLOS, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Company” or “Company management”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that members of its management team will participate in the following upcoming investor conferences:
  - Citi's 2026 Biopharma Back to School Conference: Biomea will participate in one-on-one investor meetings on September 10, 2026, in New York, NY.
  - H.C. Wainwright 28^th Annual Global Investment Conference: Biomea will present at 11:00 a.m. ET on September 15, 2026, in New York, NY. Management will also participate in one-on-one investor meetings

StreetInsider.com News Articles

Form 8-K Biomea Fusion, Inc. For: Oct 13

Biomea Fusion (BMEA) Reiterated at Market Outperform by Citizens on BMF-650 Ph1 Data

Biomea Fusion reports Phase 1 weight loss data for oral GLP-1 drug

Biomea Fusion Announces Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist

Biomea Fusion Announces Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist

Biomea Fusion to release Phase I data for oral GLP-1 drug BMF-650

Biomea Fusion to Announce Phase I Results for BMF-650, Its Next-Generation Oral Small-Molecule GLP-1 Receptor Agonist

Biomea Fusion to Announce Phase I Results for BMF-650, Its Next-Generation Oral Small-Molecule GLP-1 Receptor Agonist

Brookline Capital Markets Starts Biomea Fusion Inc. (BMEA) at Buy

Brookline Capital Markets Starts Biomea Fusion Inc. (BMEA) at Buy

Brookline Capital Markets Starts Biomea Fusion Inc. (BMEA) at Buy

Biomea Fusion (BMEA) Reiterated at Market Outperform by Citizens - Time to 'Revisit This Story'

Biomea Fusion cancels planned public offering citing market conditions

Biomea Fusion Announces Termination of Proposed Public Offering of Securities

Biomea Fusion Announces Termination of Proposed Public Offering of Securities

Form 424B5 Biomea Fusion, Inc.

Biomea Fusion launches public offering of common stock and warrants

Biomea Fusion Announces Proposed Public Offering of Securities

Biomea Fusion Announces Proposed Public Offering of Securities

Form 8-K Biomea Fusion, Inc. For: Sep 22

Increasing unusual call volume: CYPH BMEA KHC DPRO CBRG NAVN TTAN RARE SOLZ TSSI AADX BEAM AVAV

Biomea Fusion, Inc. (BMEA) January 2.5 calls active

Increasing unusual call option volume: GPRO BMEA DPRO RARE INSW VSXY CHPT VRNS SYF EPYT

Biomea Fusion to Participate in Upcoming Investor Conferences

Biomea Fusion to Participate in Upcoming Investor Conferences